How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Q2 Results And Early RM-718 Obesity Data

Rhythm Pharmaceuticals reported stronger Q2 2026 revenues of US$71.26 million, though it still incurred a net loss of US$49.30 million. The company also released promising early Phase 2 data for its new drug RM-718 for acquired hypothalamic obesity, showing double-digit BMI reductions. This data strengthens the company's investment narrative, emphasizing the potential growth beyond its IMCIVREE franchise and the broader opportunity for its MC4R assets.